Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SHANK2 antisense RNA 1 (SHANK2-AS1) is a long non-coding RNA (lncRNA) gene affiliated with the lncRNA class and does not encode a protein product[1]. There is limited functional information publicly available about this transcript, and it is not currently considered a molecular target such as a receptor, enzyme, transporter, or transcription factor[1]. While the SHANK2 sense gene is highly relevant in neurodevelopment and neuropsychiatric disorders, SHANK2-AS1 itself is mainly classified as a non-protein-coding RNA with unclear functional significance[1]. The search results and established databases identify SHANK2-AS1 as a long non-coding RNA, not as a protein-coding therapeutic target or receptor. It should not be confused with the SHANK2 protein, which is a synaptic scaffold protein implicated in autism spectrum disorder and related to synaptic function[2][3][4]. There is no evidence from the results that SHANK2-AS1 is currently utilized or explored as a direct therapeutic target or biomarker, nor are there known drugs interacting with it.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SHANK2 antisense RNA 1 (SHANK2-AS1).